Genmab has been granted a patent for multispecific antibodies binding to human CD40 and CD137, with specific nucleic acid sequences outlined. The patent covers methods for preparing and using these antibodies for therapeutic purposes. GlobalData’s report on Genmab gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Genmab AS - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Genmab, Personalized cancer vaccines was a key innovation area identified from patents. Genmab's grant share as of April 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

Multispecific antibody binding to human cd40 and cd137

Source: United States Patent and Trademark Office (USPTO). Credit: Genmab AS

A recently granted patent (Publication Number: US11939388B2) discloses a nucleic acid or a set of nucleic acids encoding a multispecific antibody. The multispecific antibody comprises a first binding arm that binds to human CD40 and a second binding arm that binds to human CD137. The sequences of the heavy and light chain variable regions, including the complementarity-determining regions (CDRs), are specified in the claims, providing a detailed description of the antibody structure.

Furthermore, the patent claims cover an expression vector comprising the nucleic acid encoding the multispecific antibody, as well as a host cell containing the expression vector. The host cell can be a recombinant eukaryotic, prokaryotic, or microbial cell. The claims also detail the sequences of the heavy and light chains, specifying the CDRs and framework sequences for both the first and second antigen-binding regions. Additionally, the patent includes information on the isotype of the heavy chains, with options for IgG subclasses. The claims further describe specific amino acid substitutions in the heavy chains, highlighting the uniqueness of the multispecific antibody's structure. Overall, the patent provides a comprehensive overview of the nucleic acids, expression vectors, and host cells involved in producing the multispecific antibody with dual antigen-binding capabilities.

To know more about GlobalData’s detailed insights on Genmab, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies